FlutiCare™ Will Be the Third Branded Fluticasone Propionate Nasal Spray Sold in the United States
Innovus Pharmaceuticals, Inc. (the “Company” or “Innovus Pharma”) (OTCQB Venture Market: INNV) and its partner West-Ward Pharmaceuticals International Limited (“WWPIL”), a wholly-owned subsidiary of Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), today announced that WWPIL will provide the Company with the rights to launch its branded, fluticasone propionate nasal spray USP, 50 mcg per spray (FlutiCare™), under WWPIL’s FDA approved abbreviated new drug application (“ANDA”) No. 207957, in the United States in the second half of 2017. FlutiCare™ is the first and only nationally branded OTC product under approved ANDA No. 207957 in the U.S. market.
